Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

Thermo Fisher Scientific Showcases Large-scale Precision Medicine Research Studies in Genotyping

http://www.prweb.com/releases/2017/09/prweb14726130.htm

In this webinar, which LabRoots will host October 25, attendees will gain a better understanding of how the recently developed Axiom Precision Medicine Research Array can be used in a wide variety of disease and therapeutic research areas.

Yorba Linda, Ca (PRWEB) September 27, 2017 — As more is discovered about the implications of genetic variation in 21st century medicine, the utilization of genotyping as a molecular tool both in the research and clinical setting is as important and popular as ever. This presentation will exemplify the power and precision of the Applied BiosystemsTM AxiomTM Genotyping Platform in several settings.

In this webinar, which is sponsored by Thermo Fisher Scientific, participants will learn of the flexibility and accuracy of the Axiom Genotyping platform through comprehensive demonstration, as well as how it can be used to power large-scale genomic studies. They will learn about and discuss the Applied BiosystemsTM PharmacoScan Solution for pharmacogenomics research and its usefulness in clinical research trials for stratifying populations.

Examples will include the use of Applied BiosystemsTM AxiomTM Genotyping Arrays in the Department of Veterans Affairs’ Million Veteran Program (MVP), the use of the Applied BiosystemsTM AxiomTM Precision Medicine Research Array, the use of the PharmacoScan Solution for pharmacogenetics, as well as using a unique custom array for potential dementia risk assessment.

Dr. Mark Bouzyk, co-founder and CSO of AKESOgen, Inc., will be the speaker for this event.

Bouzyk currently serves as co-founder and chief scientific officer of AKESOgen, Inc., a genomics, pharmacogenomics and biobanking company. Prior to AKESOgen, he spent five years as a faculty member in the Department of Human Genetics at Emory University. Bouzyk earned his doctorate degree in human molecular genetics from the University of Hertfordshire; his interests lie in Pharmacogenetics as well as candidate gene and genomic association studies to identify genes for both common and rare diseases.

For Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with revenues of $18 billion and more than 55,000 employees globally. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. Through our premier brands – Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific and Unity Lab Services – we offer an unmatched combination of innovative technologies, purchasing convenience and comprehensive support. For more information, please visit www.thermofisher.com.

About LabRoots

LabRootsis the leading scientific social networking website, which provides daily scientific trending news, as well as produces educational virtual events and webinars, on the latest discoveries and advancements in science. Contributing to the advancement of science through content sharing capabilities, LabRoots is a powerful advocate in amplifying global networks and communities. Founded in 2008, LabRoots emphasizes digital innovation in scientific collaboration and learning, and is a primary source for current scientific news, webinars, virtual conferences, and more. LabRoots has grown into the world’s largest series of virtual events within the Life Sciences and Clinical Diagnostics community.

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
AKESOgen

For the Third Year in a Row AKESOgen makes Annual List of America’s Fastest-Growing Private Companies—the Inc.500

AKESOgen Ranks as the No. 33 Healthcare Company and 448th Overall on the 2017 Inc.500

NEW YORK and ATLANTA August 16, 2017Inc. magazine today ranked AKESOgen, 33rd as a Healthcare company and 448th overall on its 36th annual Inc. 500, the most prestigious ranking of the nation’s fastest-growing private companies. The list represents a unique look at the most successful companies within the American economy’s most dynamic segment— its independent small businesses. Companies such as Microsoft, Dell, Domino’s Pizza, Pandora, Timberland, LinkedIn, Yelp, Zillow, and many other well-known names gained their first national exposure as honorees of the Inc. 500|5000.

 

“For the third consecutive year, we are delighted to be recognized as an Inc.500 honoree, sharing a pedigree with Intuit, Zappos, Under Armour, GoPro, Timberland, Clif Bar, Patagonia, Oracle, Box, Grubhub, and dozens of other Inc.500 alumni that have gone on to be household names.” commented AKESOgen CEO Robert Boisjoli.

 

“Understanding your own genetic make up and what your DNA says about you is becoming more and more a part of our everyday lives and will only continue to increase – especially with new technologies which make this information more and more accessible to the public. We are fortunate to be front and center in this new wave of emerging precision medicine molecular capabilities which are rapidly becoming mainstrain in our society.” says Mark Bouzyk, PhD, AKESOgen’s Chief Scientific Officer.

 

The 2017 Inc. 5000, unveiled online at Inc.com and with the top 500 companies featured in the September issue of Inc. is the most competitive crop in the list’s history. The average company on the list achieved a mind-boggling three-year average growth of 481%. The Inc. 5000’s aggregate revenue is $206 billion, and the companies on the list collectively generated 619,500 jobs over the past three years. Complete results of the Inc. 5000, including company profiles and an interactive database that can be sorted by industry, region, and other criteria, can be found at www.inc.com/inc5000.

 

“The Inc. 5000 is the most persuasive evidence I know that the American Dream is still alive,” says Inc. President and Editor-In-Chief Eric Schurenberg. “The founders and CEOs of the Inc. 5000 tell us they think determination, risk taking, and vision were the keys to their success, and I believe them.”

 

About Inc. Media:

Founded in 1979 and acquired in 2005 by Mansueto Ventures, Inc. is the only major brand dedicated exclusively to owners and managers of growing private companies, with the aim to deliver real solutions for today’s innovative company builders. Winner of the National Magazine Award for General Excellence in both 2014 and 2012. Total monthly audience reach for the brand has grown significantly from 2,000,000 in 2010 to over 18,000,000 today.  For more information, visit www.inc.com.

 

For more information contact:

Inc. Media

Drew Kerr

212-849-8250

drew@four-corners.com

 

About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology, neurology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation). For more information, visit www.akesogen.com.

 

Media Contact:

Marissa Cooke, Director, Business Development and Marketing, AKESOgen, Inc. +1 770-542-0890, or mcooke@akesogen.com

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail
Helathy Aging Study

Emory and AKESOgen Partner on Healthy Aging Study

ATLANTA February 28, 2016 – Emory University School of Medicine and AKESOgen announced today their collaboration on the Emory Healthy Aging Study. The largest clinical research study ever conducted in Atlanta, the Emory Healthy Aging Study is a game changing effort to further the scientific understanding of how we age. Aiming to identify predictive markers through cutting edge technologies, the study will enable the prediction of diseases occurring more commonly in later years.

Through recruitment of thousands of study participants over the next few years, the Emory Healthy Aging Study will build an extensive database of personal health information. The data collected may also help participants, through consultation with their physician, learn more about their overall health.

As an academic medical center, Emory’s mission includes providing care for patients and researching how to provide even better care in the future. AKESOgen shares this philosophy, and is well established as one of the top College of American Pathologists (CAP) accredited providers of high quality data to both research and medical institutions. Many important medical discoveries and groundbreaking new treatments have been made at Emory, thanks to the work of Emory researchers and the contributions of study participants.

“We are delighted to be working with leading scientists at Emory on this unique and outstanding long term study on health and wellbeing which will deliver enormous benefits to the participants and the community as a whole.” commented AKESOgen’s CEO Bob Boisjoli.

“We believe our strong relationship with Emory and our excellent scientific and technical prowess in precision medicine will allow us to make important contributions to new discoveries in this exciting landmark study.” says Mark Bouzyk PhD, AKESOgen’s Chief Scientific Officer.

Over time, Emory’s diverse team of researchers will study numerous age-related diseases. Examples of these include Alzheimer’s disease, heart disease, and diabetes. AKESOgen has deep experience in precision medicine approaches in these diseases among others.

“The Emory Healthy Aging Study is an ambitious clinical research endeavor that aims to improve the lives of people so they may live healthier lives as they age,” says James Lah, MD, PhD, the principal investigator of the study and associate professor and vice-chair of the Department of Neurology at Emory.

“A study of this scale, gathering large amounts of health data across a diverse participant population, will help us learn more about a host of age-related diseases,” adds Michele Marcus, PhD, Professor of Epidemiology at Emory and a lead investigator of the study.

 About the Emory Healthy Aging Study

The Emory Healthy Aging Study is the largest clinical research study ever conducted at Emory University. It is an effort to further the scientific understanding of how people age, and to learn more about diseases that occur more commonly in later years. The Emory Healthy Aging Study seeks to enroll 100,000 people and anyone 18 years of age or older who is a U.S. resident is eligible to participate. For more information, visit https://healthyaging.emory.edu.

 About AKESOgen, Inc.

AKESOgen is an integrated Clinical Laboratory Improvement Amendments (CLIA) compliant and College of American Pathology (CAP) accredited genomics, genetics and bio-banking company that services the pharmaceutical, biotechnology, clinical, academic, and government sectors for clinical trials, diagnostic clinical testing, and research. Based in Atlanta, GA, USA, the company’s main focus is oncology and personalized medicine. AKESOgen’s services include providing high-throughput, biomarker profiling, cytogenetic arrays, sequencing, and genomics analysis utilizing different types of markers (e.g. DNA, mRNA, miRNA, and methylation) and Pathology. For more information, visit www.akesogen.com.

Media Contact:

Marissa Cooke, Director, Marketing and Business Development AKESOgen, Inc. +1 770-542-0890, or mcooke@akesogen.com

 

 

Share this Facebooktwittergoogle_plusredditlinkedinmailFacebooktwittergoogle_plusredditlinkedinmail